Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

tilvestamab

A humanized immunoglobulin (Ig) G1 monoclonal antibody directed against AXL receptor tyrosine kinase (AXL; UFO), with potential immunomodulating and antineoplastic activities. Upon administration, tilvestamab targets, binds to and inhibits the activity of AXL, which is expressed on the surfaces of a variety of cancer cell types. This prevents AXL-mediated signaling, and may inhibit tumor cell proliferation, migration and invasion. AXL, a member of the TAM (TYRO3, AXL and MER) family of receptor tyrosine kinases, is overexpressed by many tumor cell types, and plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance, tumor immune evasion and poor prognosis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:BGB 149
BGB-149
BGB149
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search